Carlos Rodríguez serves as the Director of Clinical Pharmacology and PK/PD at PharmaPolaris International, Inc., where he leverages his extensive expertise in pharmacokinetics and pharmacodynamics to guide pharmaceutical and biotechnology clients through the complexities of drug development. With a robust background in both preclinical and...
Carlos Rodríguez serves as the Director of Clinical Pharmacology and PK/PD at PharmaPolaris International, Inc., where he leverages his extensive expertise in pharmacokinetics and pharmacodynamics to guide pharmaceutical and biotechnology clients through the complexities of drug development. With a robust background in both preclinical and clinical pharmacology, Carlos plays a pivotal role in shaping strategic development plans that align with regulatory requirements and industry best practices. His work encompasses a diverse range of projects, from designing and implementing clinical trials to developing sophisticated modeling and simulation approaches that optimize drug dosing and efficacy.
In addition to his role at PharmaPolaris, Carlos contributes to academia as an Adjunct Associate Professor at The University of Michigan and an Adjunct Professor at the University of the Pacific, where he educates the next generation of pharmaceutical scientists. His dual focus on consulting and teaching allows him to remain at the forefront of emerging trends in clinical research and pharmacological innovations, ensuring that his clients benefit from the latest scientific advancements.
Carlos's proficiency in medical writing and regulatory strategy further enhances his ability to support clients in navigating the intricate landscape of drug development. His commitment to excellence in clinical development is evident in his successful track record of guiding projects from Investigational New Drug (IND) applications through to market approval. By integrating his academic insights with practical industry experience, Carlos Rodríguez exemplifies the ideal blend of knowledge and application, making him an invaluable asset to PharmaPolaris and its clients.
